HomeAI · summaries
Storia in 5 fonti
ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC - Pharmaceutical Technology
While Summit’s Harmoni-6 results drew a mixed reaction, Eli Lilly’s positive Retvemo data was expanded its potential in adjuvant NSCLC.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercebiotech.com
ASCO: Revolution Medicines confident in RAS leadership as rivals square up
This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data…
- ·
fiercepharma.com
ASCO: Lilly ties Retevmo to ‘dramatic’ outcomes in early-stage lung cancer with rare RET biomarker
UNDER EMBARGO: Sunday May 31 7AM CST/ 8AM EST | In Lilly's Libretto-432 ASCO readout, Retevmo showed an 83% reduction in disease progression or death when used as an adjuvant…
